Clinical Trials Logo
  1. Home
  2. Leukemia, Acute Lymphoblastic
  3. NCT02935543

CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL

Leukemia, Acute Lymphoblastic Clinical Trial

Official title:
Phase 2 Study of CD19-directed Chimeric Antigen Receptor-modified T Cells (CART19) for Adult Patients With Minimal Residual Disease During Upfront Treatment for Acute Lymphoblastic Leukemia

Clinical Trial Summary

This is a single center, single arm, open-label phase 2 study to determine the efficacy of autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ/4-1BB) co-stimulatory domains (referred to as "CART19" cells) in adults with minimal residual disease (MRD) during upfront treatment for CD19+ acute lymphoblastic leukemia.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02935543
Study type Interventional
Source University of Pennsylvania
Contact
Status Terminated
Phase Phase 2
Start date October 2016
Completion date December 12, 2018
View Details
See also
  Status Clinical Trial Phase
Unknown status NCT02360930 - Vincristine PK and PD in the AYA Population Compared to Younger Children N/A
Recruiting NCT05306301 - Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients Phase 2
Not yet recruiting NCT06101381 - CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma Phase 1/Phase 2
Active, not recruiting NCT05440409 - CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL
Completed NCT02393859 - Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL) Phase 3
Recruiting NCT05064787 - Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy N/A
Terminated NCT02435550 - iCare for Cancer Patients N/A
Completed NCT02799147 - GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia Phase 1/Phase 2
Terminated NCT02580981 - Acute Lymphoblastic Leukemia Therapies Informed by Genomic Analyses N/A
Recruiting NCT04307576 - A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia Phase 3
Recruiting NCT04942730 - Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe) Phase 2
Terminated NCT01761682 - Acute Lymphoblastic Leukemia Registry at Asan Medical Center
Completed NCT04327037 - Safety of Expanded Haploidentical Natural Killer Cells for Leukemia Phase 1
Terminated NCT02349178 - Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT Phase 2
Recruiting NCT04209244 - Effect of Fish Oil on Hyperlipidemia and Toxicities in Children and Young Adults With Acute Lymphoblastic Leukemia N/A
Recruiting NCT03911128 - A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
No longer available NCT00590915 - Erwinase Master Treatment Protocol N/A